Apogenix gets 25.8m cash injection for asunercept
German Apogenix AG has received a 26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
British Adendra Therapeutics closes $53m financing
The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).
US-Greek Venture gets 32m cash injection
US cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received 32m in funding by Enterprise Greece.
EC signs prepurchase agreement with Valneva
The European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Novo Nordisk snatches Dicerna
Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
LSP and EQT merge to create top-10 investment firm
Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Novartis inks US-$1.3bn deal with Dunad Therapeutics
Dunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.
Agomab Therapeutics to acquire Origo Biopharma
Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
Sofinnova Capital X Fund closed at 472m
Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
Curevac withdraws MAA of CVnCoV
German CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.